Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension
This study investigates the respirability and efficacy of peptide–micelle hybrid nanoparticles as carriers for inhalational therapy of pulmonary arterial hypertension (PAH). CARSKNKDC (CAR), a cell‐penetrating and lung‐homing peptide, conjugated polyethylene glycol–distearoyl‐phosphoethanolamine mic...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical sciences 2014-11, Vol.103 (11), p.3743-3753 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3753 |
|---|---|
| container_issue | 11 |
| container_start_page | 3743 |
| container_title | Journal of pharmaceutical sciences |
| container_volume | 103 |
| creator | Gupta, Nilesh Ibrahim, Hany M. Ahsan, Fakhrul |
| description | This study investigates the respirability and efficacy of peptide–micelle hybrid nanoparticles as carriers for inhalational therapy of pulmonary arterial hypertension (PAH). CARSKNKDC (CAR), a cell‐penetrating and lung‐homing peptide, conjugated polyethylene glycol–distearoyl‐phosphoethanolamine micelles containing fasudil, an investigational anti‐PAH drug, were prepared by solvent evaporation method and characterized for various physicochemical properties. The pharmacokinetics and pharmacological efficacy of hybrid particles containing fasudil were evaluated in healthy rats and monocrotaline‐induced PAH rats. CAR micelles containing fasudil had an entrapment efficiency of approximately 58%, showed controlled release of the drug, and were monodispersed with an average size of approximately 14nm. Nuclear magnetic resonance scan confirmed the drug's presence in the core of peptide–micelle hybrid particles. Compared with plain micelles, CAR peptide increased the cellular uptake by approximately 1.7‐fold and extended the drug half‐life by approximately fivefold. The formulations were more prone to accumulate in the pulmonary vasculature than in the peripheral blood, which is evident from the ratio of the extent of reduction of pulmonary and systemic arterial pressures. On the whole, this study demonstrates that peptide–polymer hybrid micelles can serve as inhalational carriers for PAH therapy. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3743–3753, 2014 |
| doi_str_mv | 10.1002/jps.24193 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1614209185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915303142</els_id><sourcerecordid>3465930451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5023-1f26f081eadfb3515c235c709e0b933462d2caf9a1293f72f804dbd2a52da4753</originalsourceid><addsrcrecordid>eNp1kMtuEzEUhi0EoqGw4AWQJVYspvVlPJNZVim9oFZEIqwtj32mOHLswfYUZcc7lCfkSXCblA1lZZ_jz_85-hB6S8kRJYQdr8d0xGra8WdoRgUjVUNo-xzNyhuruKi7A_QqpTUhpCFCvEQHTLCmEaSdoV9LGLM18Pvn3bXV4Bzgi20frUl4EXxW1lt_g89Umox1eAgRr1S8gQwGn4KztxC3OAecvwFeTm4TvCqNk5ghWkhYebMvgitlAVcRVP4HVa5MHaHcfbLBv0YvBuUSvNmfh-jr2cfV4qK6-nx-uTi5qrQgjFd0YM1A5hSUGXouqNCMC92SDkjfcV43zDCthk5R1vGhZcOc1KY3TAlmVN0Kfoje73LHGL5PkLJchyn6MlLShtaMdHR-T33YUTqGlCIMcox2U5aXlMh7_7L4lw_-C_tunzj1GzB_yUfhBTjeAT-sg-3_k-Sn5ZfHSL77AcXErYUok7bgNRgbQWdpgn1ikT-lwKQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1614209185</pqid></control><display><type>article</type><title>Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><creator>Gupta, Nilesh ; Ibrahim, Hany M. ; Ahsan, Fakhrul</creator><creatorcontrib>Gupta, Nilesh ; Ibrahim, Hany M. ; Ahsan, Fakhrul</creatorcontrib><description>This study investigates the respirability and efficacy of peptide–micelle hybrid nanoparticles as carriers for inhalational therapy of pulmonary arterial hypertension (PAH). CARSKNKDC (CAR), a cell‐penetrating and lung‐homing peptide, conjugated polyethylene glycol–distearoyl‐phosphoethanolamine micelles containing fasudil, an investigational anti‐PAH drug, were prepared by solvent evaporation method and characterized for various physicochemical properties. The pharmacokinetics and pharmacological efficacy of hybrid particles containing fasudil were evaluated in healthy rats and monocrotaline‐induced PAH rats. CAR micelles containing fasudil had an entrapment efficiency of approximately 58%, showed controlled release of the drug, and were monodispersed with an average size of approximately 14nm. Nuclear magnetic resonance scan confirmed the drug's presence in the core of peptide–micelle hybrid particles. Compared with plain micelles, CAR peptide increased the cellular uptake by approximately 1.7‐fold and extended the drug half‐life by approximately fivefold. The formulations were more prone to accumulate in the pulmonary vasculature than in the peripheral blood, which is evident from the ratio of the extent of reduction of pulmonary and systemic arterial pressures. On the whole, this study demonstrates that peptide–polymer hybrid micelles can serve as inhalational carriers for PAH therapy. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3743–3753, 2014</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.24193</identifier><identifier>PMID: 25266507</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage ; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives ; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - chemistry ; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacokinetics ; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - toxicity ; Administration, Inhalation ; Animals ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - chemistry ; Antihypertensive Agents - pharmacokinetics ; Antihypertensive Agents - toxicity ; Arterial Pressure - drug effects ; Arterioles - drug effects ; Arterioles - metabolism ; Arterioles - physiopathology ; Cell-Penetrating Peptides - administration & dosage ; Cell-Penetrating Peptides - chemistry ; Cell-Penetrating Peptides - metabolism ; Cell-Penetrating Peptides - toxicity ; Chemistry, Pharmaceutical ; controlled release ; Delayed-Action Preparations ; Disease Models, Animal ; Drug Carriers ; encapsulation ; Ethanolamines - chemistry ; Ethanolamines - toxicity ; formulation ; Hypertension, Pulmonary - chemically induced ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - metabolism ; Hypertension, Pulmonary - physiopathology ; in vitro models ; Injections, Intravenous ; Magnetic Resonance Spectroscopy ; Male ; micelle ; Micelles ; Monocrotaline ; nanotechnology ; Oligopeptides - administration & dosage ; Oligopeptides - chemistry ; Oligopeptides - metabolism ; Oligopeptides - toxicity ; Particle Size ; phospholipids ; Polyethylene Glycols - chemistry ; Polyethylene Glycols - toxicity ; Pulmonary Artery - drug effects ; Pulmonary Artery - metabolism ; Pulmonary Artery - physiopathology ; pulmonary delivery/absorption ; Rats, Sprague-Dawley ; Solubility ; targeted drug delivery ; Technology, Pharmaceutical - methods ; toxicity</subject><ispartof>Journal of pharmaceutical sciences, 2014-11, Vol.103 (11), p.3743-3753</ispartof><rights>2014 Wiley Periodicals, Inc. and the American Pharmacists Association</rights><rights>2014 Wiley Periodicals, Inc. and the American Pharmacists Association.</rights><rights>Copyright © 2014 Wiley Periodicals, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5023-1f26f081eadfb3515c235c709e0b933462d2caf9a1293f72f804dbd2a52da4753</citedby><cites>FETCH-LOGICAL-c5023-1f26f081eadfb3515c235c709e0b933462d2caf9a1293f72f804dbd2a52da4753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.24193$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.24193$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25266507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Nilesh</creatorcontrib><creatorcontrib>Ibrahim, Hany M.</creatorcontrib><creatorcontrib>Ahsan, Fakhrul</creatorcontrib><title>Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>This study investigates the respirability and efficacy of peptide–micelle hybrid nanoparticles as carriers for inhalational therapy of pulmonary arterial hypertension (PAH). CARSKNKDC (CAR), a cell‐penetrating and lung‐homing peptide, conjugated polyethylene glycol–distearoyl‐phosphoethanolamine micelles containing fasudil, an investigational anti‐PAH drug, were prepared by solvent evaporation method and characterized for various physicochemical properties. The pharmacokinetics and pharmacological efficacy of hybrid particles containing fasudil were evaluated in healthy rats and monocrotaline‐induced PAH rats. CAR micelles containing fasudil had an entrapment efficiency of approximately 58%, showed controlled release of the drug, and were monodispersed with an average size of approximately 14nm. Nuclear magnetic resonance scan confirmed the drug's presence in the core of peptide–micelle hybrid particles. Compared with plain micelles, CAR peptide increased the cellular uptake by approximately 1.7‐fold and extended the drug half‐life by approximately fivefold. The formulations were more prone to accumulate in the pulmonary vasculature than in the peripheral blood, which is evident from the ratio of the extent of reduction of pulmonary and systemic arterial pressures. On the whole, this study demonstrates that peptide–polymer hybrid micelles can serve as inhalational carriers for PAH therapy. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3743–3753, 2014</description><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage</subject><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives</subject><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - chemistry</subject><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacokinetics</subject><subject>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - toxicity</subject><subject>Administration, Inhalation</subject><subject>Animals</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - chemistry</subject><subject>Antihypertensive Agents - pharmacokinetics</subject><subject>Antihypertensive Agents - toxicity</subject><subject>Arterial Pressure - drug effects</subject><subject>Arterioles - drug effects</subject><subject>Arterioles - metabolism</subject><subject>Arterioles - physiopathology</subject><subject>Cell-Penetrating Peptides - administration & dosage</subject><subject>Cell-Penetrating Peptides - chemistry</subject><subject>Cell-Penetrating Peptides - metabolism</subject><subject>Cell-Penetrating Peptides - toxicity</subject><subject>Chemistry, Pharmaceutical</subject><subject>controlled release</subject><subject>Delayed-Action Preparations</subject><subject>Disease Models, Animal</subject><subject>Drug Carriers</subject><subject>encapsulation</subject><subject>Ethanolamines - chemistry</subject><subject>Ethanolamines - toxicity</subject><subject>formulation</subject><subject>Hypertension, Pulmonary - chemically induced</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - metabolism</subject><subject>Hypertension, Pulmonary - physiopathology</subject><subject>in vitro models</subject><subject>Injections, Intravenous</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Male</subject><subject>micelle</subject><subject>Micelles</subject><subject>Monocrotaline</subject><subject>nanotechnology</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - chemistry</subject><subject>Oligopeptides - metabolism</subject><subject>Oligopeptides - toxicity</subject><subject>Particle Size</subject><subject>phospholipids</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Polyethylene Glycols - toxicity</subject><subject>Pulmonary Artery - drug effects</subject><subject>Pulmonary Artery - metabolism</subject><subject>Pulmonary Artery - physiopathology</subject><subject>pulmonary delivery/absorption</subject><subject>Rats, Sprague-Dawley</subject><subject>Solubility</subject><subject>targeted drug delivery</subject><subject>Technology, Pharmaceutical - methods</subject><subject>toxicity</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtuEzEUhi0EoqGw4AWQJVYspvVlPJNZVim9oFZEIqwtj32mOHLswfYUZcc7lCfkSXCblA1lZZ_jz_85-hB6S8kRJYQdr8d0xGra8WdoRgUjVUNo-xzNyhuruKi7A_QqpTUhpCFCvEQHTLCmEaSdoV9LGLM18Pvn3bXV4Bzgi20frUl4EXxW1lt_g89Umox1eAgRr1S8gQwGn4KztxC3OAecvwFeTm4TvCqNk5ghWkhYebMvgitlAVcRVP4HVa5MHaHcfbLBv0YvBuUSvNmfh-jr2cfV4qK6-nx-uTi5qrQgjFd0YM1A5hSUGXouqNCMC92SDkjfcV43zDCthk5R1vGhZcOc1KY3TAlmVN0Kfoje73LHGL5PkLJchyn6MlLShtaMdHR-T33YUTqGlCIMcox2U5aXlMh7_7L4lw_-C_tunzj1GzB_yUfhBTjeAT-sg-3_k-Sn5ZfHSL77AcXErYUok7bgNRgbQWdpgn1ikT-lwKQg</recordid><startdate>201411</startdate><enddate>201411</enddate><creator>Gupta, Nilesh</creator><creator>Ibrahim, Hany M.</creator><creator>Ahsan, Fakhrul</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201411</creationdate><title>Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension</title><author>Gupta, Nilesh ; Ibrahim, Hany M. ; Ahsan, Fakhrul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5023-1f26f081eadfb3515c235c709e0b933462d2caf9a1293f72f804dbd2a52da4753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage</topic><topic>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives</topic><topic>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - chemistry</topic><topic>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacokinetics</topic><topic>1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - toxicity</topic><topic>Administration, Inhalation</topic><topic>Animals</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - chemistry</topic><topic>Antihypertensive Agents - pharmacokinetics</topic><topic>Antihypertensive Agents - toxicity</topic><topic>Arterial Pressure - drug effects</topic><topic>Arterioles - drug effects</topic><topic>Arterioles - metabolism</topic><topic>Arterioles - physiopathology</topic><topic>Cell-Penetrating Peptides - administration & dosage</topic><topic>Cell-Penetrating Peptides - chemistry</topic><topic>Cell-Penetrating Peptides - metabolism</topic><topic>Cell-Penetrating Peptides - toxicity</topic><topic>Chemistry, Pharmaceutical</topic><topic>controlled release</topic><topic>Delayed-Action Preparations</topic><topic>Disease Models, Animal</topic><topic>Drug Carriers</topic><topic>encapsulation</topic><topic>Ethanolamines - chemistry</topic><topic>Ethanolamines - toxicity</topic><topic>formulation</topic><topic>Hypertension, Pulmonary - chemically induced</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - metabolism</topic><topic>Hypertension, Pulmonary - physiopathology</topic><topic>in vitro models</topic><topic>Injections, Intravenous</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Male</topic><topic>micelle</topic><topic>Micelles</topic><topic>Monocrotaline</topic><topic>nanotechnology</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - chemistry</topic><topic>Oligopeptides - metabolism</topic><topic>Oligopeptides - toxicity</topic><topic>Particle Size</topic><topic>phospholipids</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Polyethylene Glycols - toxicity</topic><topic>Pulmonary Artery - drug effects</topic><topic>Pulmonary Artery - metabolism</topic><topic>Pulmonary Artery - physiopathology</topic><topic>pulmonary delivery/absorption</topic><topic>Rats, Sprague-Dawley</topic><topic>Solubility</topic><topic>targeted drug delivery</topic><topic>Technology, Pharmaceutical - methods</topic><topic>toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Nilesh</creatorcontrib><creatorcontrib>Ibrahim, Hany M.</creatorcontrib><creatorcontrib>Ahsan, Fakhrul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Nilesh</au><au>Ibrahim, Hany M.</au><au>Ahsan, Fakhrul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2014-11</date><risdate>2014</risdate><volume>103</volume><issue>11</issue><spage>3743</spage><epage>3753</epage><pages>3743-3753</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>This study investigates the respirability and efficacy of peptide–micelle hybrid nanoparticles as carriers for inhalational therapy of pulmonary arterial hypertension (PAH). CARSKNKDC (CAR), a cell‐penetrating and lung‐homing peptide, conjugated polyethylene glycol–distearoyl‐phosphoethanolamine micelles containing fasudil, an investigational anti‐PAH drug, were prepared by solvent evaporation method and characterized for various physicochemical properties. The pharmacokinetics and pharmacological efficacy of hybrid particles containing fasudil were evaluated in healthy rats and monocrotaline‐induced PAH rats. CAR micelles containing fasudil had an entrapment efficiency of approximately 58%, showed controlled release of the drug, and were monodispersed with an average size of approximately 14nm. Nuclear magnetic resonance scan confirmed the drug's presence in the core of peptide–micelle hybrid particles. Compared with plain micelles, CAR peptide increased the cellular uptake by approximately 1.7‐fold and extended the drug half‐life by approximately fivefold. The formulations were more prone to accumulate in the pulmonary vasculature than in the peripheral blood, which is evident from the ratio of the extent of reduction of pulmonary and systemic arterial pressures. On the whole, this study demonstrates that peptide–polymer hybrid micelles can serve as inhalational carriers for PAH therapy. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3743–3753, 2014</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25266507</pmid><doi>10.1002/jps.24193</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3549 |
| ispartof | Journal of pharmaceutical sciences, 2014-11, Vol.103 (11), p.3743-3753 |
| issn | 0022-3549 1520-6017 |
| language | eng |
| recordid | cdi_proquest_journals_1614209185 |
| source | MEDLINE; Wiley Online Library All Journals; Alma/SFX Local Collection |
| subjects | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - chemistry 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacokinetics 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - toxicity Administration, Inhalation Animals Antihypertensive Agents - administration & dosage Antihypertensive Agents - chemistry Antihypertensive Agents - pharmacokinetics Antihypertensive Agents - toxicity Arterial Pressure - drug effects Arterioles - drug effects Arterioles - metabolism Arterioles - physiopathology Cell-Penetrating Peptides - administration & dosage Cell-Penetrating Peptides - chemistry Cell-Penetrating Peptides - metabolism Cell-Penetrating Peptides - toxicity Chemistry, Pharmaceutical controlled release Delayed-Action Preparations Disease Models, Animal Drug Carriers encapsulation Ethanolamines - chemistry Ethanolamines - toxicity formulation Hypertension, Pulmonary - chemically induced Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - metabolism Hypertension, Pulmonary - physiopathology in vitro models Injections, Intravenous Magnetic Resonance Spectroscopy Male micelle Micelles Monocrotaline nanotechnology Oligopeptides - administration & dosage Oligopeptides - chemistry Oligopeptides - metabolism Oligopeptides - toxicity Particle Size phospholipids Polyethylene Glycols - chemistry Polyethylene Glycols - toxicity Pulmonary Artery - drug effects Pulmonary Artery - metabolism Pulmonary Artery - physiopathology pulmonary delivery/absorption Rats, Sprague-Dawley Solubility targeted drug delivery Technology, Pharmaceutical - methods toxicity |
| title | Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A56%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peptide%E2%80%93Micelle%20Hybrids%20Containing%20Fasudil%20for%20Targeted%20Delivery%20to%20the%20Pulmonary%20Arteries%20and%20Arterioles%20to%20Treat%20Pulmonary%20Arterial%20Hypertension&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Gupta,%20Nilesh&rft.date=2014-11&rft.volume=103&rft.issue=11&rft.spage=3743&rft.epage=3753&rft.pages=3743-3753&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.24193&rft_dat=%3Cproquest_cross%3E3465930451%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1614209185&rft_id=info:pmid/25266507&rft_els_id=S0022354915303142&rfr_iscdi=true |